After Long Wait, Aβ Oligomer Detangler Poised for Phase 2

While the trials, tribulations, and successes of Aβ immunotherapy were commanding Alzheimerologists' rapt attention, a different anti-amyloid approach has been quietly moving forward on the sidelines. PRI-002 - a small molecule that disassembles Aβ oligomer - is about to start a sizeable Phase 2 trial....

more information on

Alzforum Newsletter November 13, 2023